Testing a drug injected into tumors for soft tissue sarcoma
Part of Cancer clinical trials.
This trial tests whether a medicine injected directly into a tumor can shrink or control advanced soft tissue sarcoma. It mainly looks for people whose tumors can be safely injected with a hand exam or ultrasound.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can sign consent and follow study instructions
- You have confirmed soft tissue sarcoma that is advanced or has spread, and your tumor can be injected into (by touch or ultrasound)
- Your general health is good enough (ECOG 0–2) and you’re expected to live more than 12 weeks
- Your kidneys and liver work well enough for the study treatment
- You must not be planning nearby radiation or injection of the same tumor within the last 28 days
- You cannot have certain high-risk situations (like major blood clotting problems, active brain metastases, or unsafe tumor locations near major blood vessels)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests trabectedin (in tTF-NGR study) for people with advanced or metastatic soft-tissue sarcoma whose first treatment with anthracycline drugs didn’t work (or can’t be used). It aims to see if this approach works better than the study comparison treatment, using tumor response and other safety outcomes.
This study is testing a new blood test that looks for circulating tumor cells in your blood. The goal is to see if this test can help doctors make better treatment decisions for soft tissue sarcoma, potentially improving how the disease is managed.
This study tests whether giving radiation, chemotherapy, and immunotherapy together can control high-risk soft tissue sarcoma that is hard to remove or may come back after surgery. It may help by attacking cancer in different ways, including boosting the immune system.
This trial tests an experimental drug, SOT106, that targets a specific marker on sarcoma cells. It aims to see if the drug is safe and effective in treating advanced osteosarcoma or soft tissue sarcoma when other treatments have not helped.
This trial tests trabectedin plus ipilimumab and nivolumab in people with advanced soft-tissue sarcoma that has already been treated. It aims to see how well this combination works and how safely it can be given.
This trial tests a combination of radiation therapy and two drugs (anlotinib and penpulimab) given before surgery for soft tissue sarcoma. The goal is to see if this approach can shrink tumors and improve outcomes.
Hear when a new Soft Tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.